Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9454360 | 0.87 | IDO1 (0.52) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL9454350 | 0.87 | IDO1 (0.52) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL4485099 | 0.83 | IDO1 (0.58) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL29471945 | 0.83 | IDO1 (0.58) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL15750592 | 0.83 | IDO1 (0.58) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL3211483 | 0.83 | IDO1 (0.58) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL14489499 | 0.82 | IDO1 (0.75) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL19920014 | 0.81 | IDO1 (0.59) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL27954179 | 0.81 | IDO1 (0.55) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 | |
| SCHEMBL4475935 | 0.81 | IDO1 (0.55) | IDO1CYP3A4CYP19A1CYP2A6CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101151246-B | 1-benzylindole-2-carboxamide derivatives | ORGANON NV | 2011-04-13 | — | — | CN | disclosed |
| US-7671080-B2 | 1-benzylindole-2-carboxamide derivatives | N.V. ORGANON (NL) | 2010-03-02 | — | — | US | disclosed |
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | N.V. ORGANON (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1940788-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. Organon (NL) | 2008-07-09 | — | — | EP | disclosed |
| CN-101151246-A | 1-benzylindole-2-carboxamide derivatives | ORGANON NV (NL) | 2008-03-26 | — | — | CN | disclosed |
| WO-2006100208-A9 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | ORGANON NV (NL) | 2007-11-22 | — | — | WO | disclosed |
| WO-2006100208-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2006-09-28 | — | — | WO | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0395768-A1 | SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-07 | — | — | EP | disclosed |
| CN-1042910-A | The allylamine derivatives that replaces, their production method and application thereof | BANYU PHARMA CO LTD (JP) | 1990-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | CNR2, CNR1, HTR2C | IDO1 42/4885CYP3A4 327/4885CYP19A1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.